NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

A Natural History Study of Children and Adults With Olfactory Neuroblastoma

Recruiting

Conditions: Olfactory Neuroblastoma
Esthesioneuroblastoma

First Posted Date: 2021-02-16

Last Posted Date: 2025-04-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 525

Registration Number: NCT04755205

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

Phase 2

Active, not recruiting

Conditions: Locally Advanced Rectal Adenocarcinoma
Stage II Rectal Cancer AJCC v8
Stage III Rectal Cancer AJCC v8

Interventions: Procedure: Computed Tomography
Biological: Ipilimumab
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Radiation: Radiation Therapy
Procedure: Sigmoidoscopy
Procedure: Total Mesorectal Excision

First Posted Date: 2021-02-12

Last Posted Date: 2025-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT04751370

Locations: 🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 213 locations

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

Phase 1

Completed

Conditions: High Risk Neuroblastoma
Recurrent Neuroblastoma
Recurrent Osteosarcoma
Refractory Neuroblastoma
Resectable Osteosarcoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Biological: Dinutuximab
Procedure: Magnetic Resonance Imaging
Biological: Magrolimab
Procedure: Resection

First Posted Date: 2021-02-12

Last Posted Date: 2025-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT04751383

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States

and more 8 locations

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Phase 1

Active, not recruiting

Conditions: Neuroendocrine Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Lutetium Lu 177 Dotatate
Procedure: Magnetic Resonance Imaging
Drug: Peposertib

First Posted Date: 2021-02-11

Last Posted Date: 2025-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT04750954

Locations: 🇺🇸
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

and more 2 locations

NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 Data

Active, not recruiting

Conditions: Cancer
Mortality
Chronic Diseases

First Posted Date: 2021-02-11

Last Posted Date: 2025-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 566398

Registration Number: NCT04750915

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Phase 1

Recruiting

Conditions: Neurofibromatosis 1

Interventions: Drug: Abemaciclib

First Posted Date: 2021-02-11

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT04750928

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis

Active, not recruiting

Conditions: KSHV Associated Multicentric Castleman Disease
Primary Effusion Lymphoma
Kaposi Sarcoma
IL-6 Related KSHV Associated Cytokine Syndrome

First Posted Date: 2021-02-08

Last Posted Date: 2025-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT04742387

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2

Active, not recruiting

Conditions: Fallopian Tube Mucinous Adenocarcinoma
Ovarian Seromucinous Carcinoma
Platinum-Refractory Fallopian Tube Carcinoma
Platinum-Refractory Ovarian Carcinoma
Platinum-Refractory Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Clear Cell Adenocarcinoma
Recurrent Fallopian Tube Endometrioid Adenocarcinoma
Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
Recurrent Fallopian Tube Mucinous Adenocarcinoma
Recurrent Fallopian Tube Transitional Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Drug: Cediranib Maleate
Procedure: Computed Tomography
Procedure: Computed Tomography with Contrast
Procedure: Echocardiography Test
Biological: Durvalumab
Procedure: Magnetic Resonance Imaging
Drug: Olaparib
Drug: Paclitaxel
Procedure: Multigated Acquisition Scan
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Drug: Topotecan Hydrochloride

First Posted Date: 2021-02-05

Last Posted Date: 2025-04-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT04739800

Locations: 🇺🇸
CoxHealth South Hospital, Springfield, Missouri, United States
🇺🇸
Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States
🇺🇸
TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States

and more 388 locations

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Phase 1

Recruiting

Conditions: Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Burkitt Lymphoma

Interventions: Biological: obinutuzumab
Drug: prednisone
Drug: Revlimid
Biological: Polatuzumab
Drug: ibrutinib
Drug: venetoclax

First Posted Date: 2021-02-05

Last Posted Date: 2025-03-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT04739813

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Phase 2

Active, not recruiting

Conditions: Recurrent Glioblastoma
Diffuse Astrocytoma, IDH-Wildtype

Interventions: Biological: Atezolizumab
Procedure: Biospecimen Collection
Radiation: Fractionated Stereotactic Radiation Therapy
Procedure: Conventional Surgery
Procedure: Magnetic Resonance Imaging
Biological: Tocilizumab

First Posted Date: 2021-01-29

Last Posted Date: 2025-04-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT04729959

Locations: 🇺🇸
Overlook Hospital, Summit, New Jersey, United States
🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States
🇺🇸
Kaiser Permanente-Bellflower, Bellflower, California, United States

and more 108 locations

Home Terms & Conditions Privacy Policy